Related Experiment Video
Updated: Dec 13, 2025
Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases
Published on: August 23, 2024
"Star" miR-34a and CXCR4 antagonist based nanoplex for binary cooperative migration treatment against metastatic
Xue Yang1, Fang Gao1, Wenan Zhang1
1State Key Laboratory of Natural Medicines, Department of Pharmaceutics, China Pharmaceutical University, Nanjing 210009, China.
Abstract:
Invasion and metastasis of tumor cells is one of the major obstacles in cancer therapy. The process of tumor metastasis and diffusion is coordinated by multiple pathways associated with chemokine signals and migration microenvironment. In our previous work, chemokine CXC receptor 4 (CXCR4) antagonists showed significant anti-metastatic effects by blocking the CXCR4/stromal cell-derived factor-1(SDF-1) axis in pancreatic cancer and breast cancer. Here, we proposed to achieve migration chain-treatment for metastatic tumors by introducing a cell adhesion molecules CD44 inhibitor (Star miR-34a) to deprive of cell migration capability on the basis of CXCR4 antagonism (cyclam monomer, CM). Dextrin modified 1.8 k PEI with CM-end was prepared to deliver therapeutic miR-34a (named DPC/miR-34a) for efficient anti-metastasis by downregulating adhesion protein CD44 and targeting the CXCR4/SDF-1 axis. Additionally, reduced expression of the anti-apoptotic protein Bcl2 caused by miR-34a could enhance the anti-tumor efficacy of DPC/miR-34a nanoplex administration. Compared with inhibition of the CXCR4/SDF-1 axis or CD44 expression, the multidimensional therapy (DPC/miR-34a) exhibited considerable suppression of cancer cell invasion as assessed by an in vitro cell invasion assay and in vivo anti-metastasis model. Moreover, DPC/miR-34a demonstrated a superior antitumor and anti-metastatic efficacy both in lung metastatic model and orthotopic MDA-MB-231 tumor models, thus providing an efficient approach for combating metastatic tumors.
Insights
This study developed a novel nanoplex therapy (DPC/miR-34a) that simultaneously targets CXCR4 and CD44 pathways. This multidimensional approach effectively inhibits cancer cell migration and metastasis, offering a promising strategy for treating advanced cancers.
Area of Science:
- Oncology
- Nanomedicine
- Molecular Biology
Background:
- Tumor cell invasion and metastasis are critical challenges in cancer therapy.
- The CXCR4/stromal cell-derived factor-1 (SDF-1) axis and cell adhesion molecule CD44 are key regulators of cancer cell migration.
- Previous research demonstrated the anti-metastatic potential of CXCR4 antagonists.
Purpose of the Study:
- To develop a multidimensional therapy combining CXCR4 antagonism with CD44 inhibition for enhanced anti-metastatic effects.
- To create a novel nanocarrier system (DPC/miR-34a) for co-delivery of therapeutic agents targeting migration pathways.
- To evaluate the efficacy of this combined therapy in preclinical models of cancer metastasis.
Main Methods:
- Preparation of dextrin-modified 1.8k PEI nanoplex loaded with miR-34a and cyclam monomer (CM).
- In vitro cell invasion assays to assess the anti-migratory effects.
- In vivo studies using lung metastasis and orthotopic MDA-MB-231 tumor models to evaluate anti-tumor and anti-metastatic efficacy.
Main Results:
- The DPC/miR-34a nanoplex effectively downregulated CD44 expression and targeted the CXCR4/SDF-1 axis.
- Combined therapy demonstrated significant suppression of cancer cell invasion compared to single-target inhibition.
- DPC/miR-34a exhibited superior anti-tumor and anti-metastatic efficacy in both lung metastasis and orthotopic tumor models.
- Reduced Bcl2 expression was observed, potentially enhancing anti-tumor effects.
Conclusions:
- The DPC/miR-34a nanoplex provides an efficient multidimensional therapeutic approach for combating metastatic tumors.
- This strategy effectively inhibits cancer cell migration and metastasis by targeting key pathways.
- The developed nanomedicine holds promise for improving outcomes in patients with advanced cancers.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...